1. Introduction {#s0005}
===============

Doxorubicin (DOX) is an effective anticancer agent that revered extensive recognition in recent years for the management of several types of cancers. However it\'s harmful perspective i.e., cardiotoxicity, hepatic damages, and nephrotoxicity have reticent its clinical practice ([@b0290]). DOX-impelled renal toxicity may be an element of a multi-organ impairment facilitated primarily due to the free radicals accumulation, ultimately inducing the membrane lipid peroxidation ([@b0115]). Stimulation of apoptosis and inflection of nitric oxide (NO) are supplementary sources that may intricate in lethal influences accompanying DOX therapy. The likely role of DOX in NOS metabolism governs through direct or indirect incitement of NO generation as a sequel of augmented free radical production. Free radical generation and/or NO release persuaded by DOX is utterly responsible for the DOX-induced harmfulness ([@b0200], [@b0075]). Furthermore, DOX can encourage nephrotoxicity via its detrimental effects on renal tissue, as it accrues especially in the kidney; amplified permeability of glomerular capillary and induce tubular degeneration ([@b0190]). DOX-prompted harmfulness to other tissues like heart and liver possibly will alter blood supply to the kidney and change the xenobiotic reclamation, henceforth periphrastically executing nephropathy. A lot of antioxidant combinations have been recommended as chemo-deterrent for DOX-persuaded toxicity ([@b0120], [@b0310]).

*Acacia hydaspica* R. Parker synonyms *Acacia eburnean* (family: Leguminosae). The vernacular name of the plant is Pahari Kikar, Kikar; Marmat. The seeds and bark possess high amount of tannins ([@b0100], [@b0150]). *A. hydaspica* exhibited anticancer, antioxidant ([@b0045]), anti-inflammatory ([@b0015]), cardio-protective ([@b0035], [@b0030]), protective against CP induced reproductive and hepatic toxicity ([@b0020], [@b0025]). GCMS analysis identified α-Amyrin (5.03%), 1,2-Benzenedicarboxylic acid mono (2-Ethylhexyl) ester (70.65%), Vitamin E (4.56%), Squalene (4%) and 2,6-dimethyl-N-(2-methyl-à-phenyl benzyl) aniline (2.51%) in *A. hydaspica* ([@b0040]). Bioassay-guided isolation identified 7-O-galloyl catechin, catechin, catechin gallate, and methyl gallate as major antioxidant and anticancer phytoconstituents from *A. hydaspica* ethylacetate fraction (AHE) ([@b0045], [@b0050], [@b0055]). Genus *Acacia* exposed antioxidant and nephroprotective proficiencies in animal prototypes ([@b0260]). The aqueous extract of *A. Senegal* showed significant nephroprotective potency against gentamicin (100 mg/kg) induced renal damage by lowering serum creatinine and urea levels in rats ([@b0205]). Administration of *A. nilotica* significantly inhibits cadmium chloride prompted diminution in serum globulin and albumin concentration, albumin/globulin ratio, SOD, and GPx levels by ameliorating MDA and NO content hence protected renal damages ([@b0185]). Previous studies reported that green tea polyphenols possess shielding influence counter to CP-persuaded kidney damage in rats. Polyphenols administration before CP inoculation was more operative than post-treatment in lessening CP adverse reactions on the kidney. Epigallocatechin gallate administration prevents CP induced renal damages, diminish the oxidative kidney harms and inflammatory responses ([@b0065]).

Due to the nephroprotective potential of related species and polyphenolic compounds in animal prototypes and *in vivo* antioxidant action of *A. hydaspica*. The present experiment was intended to delineate the protective perspective of the ethyl-acetate extract of *A. hydaspica* against DOX-prompted renal injuriousness and oxidative trauma in rats. We hypothesized that polyphenol-rich AHE could preclude DOX-induced nephrotoxicity due to its antioxidant properties. The effect of AHE on the antioxidant status, biochemical alterations, DNA damage, and histoarchitecture in DOX-persuaded nephrotoxicity was studied by urine analysis, renal function tests in serum, antioxidant enzymes of renal tissue, oxidative stress, DNA fragmentation and DNA damage in renal tissue, and histological examinations.

2. Materials and methods {#s0010}
========================

2.1. Collection of plant and extract preparation {#s0015}
------------------------------------------------

Aerial parts of *A. hydaspica* were taken from Kirpa Charah village Islamabad, Pakistan, and were recognized by Dr. Sumaira Sahreen and given Accession No. 0642531. The specimen was submitted in the Herbarium of Pakistan, Museum of Natural History, Islamabad. The detailed process of extract preparation and fractionation has been described in our earlier reports on *A. hydaspica* ([@b0015]), and its ethyl acetate extract (AHE); the most bioactive extract under *in vitro* and *in vivo* investigations and having bioactive polyphenols ([@b0055], [@b0015], [@b0035]) was selected for the current investigation.

2.2. Preparation of samples for dosage {#s0020}
--------------------------------------

Doxorubicin (DOX) injection (Sigma-Aldrich: St. Louis, MO, U.S.A.) was diluted in saline to set quantity for inoculation. A total dose of 18 mg/kg b.w was injected into rats in the course of the experiment ([@b0315]). Silymarin and AHE were prepared freshly in distilled water just before dosing ([@b0245]).

2.3. Scheme of the experiment {#s0025}
-----------------------------

Sprague Dawley male rats (200--230 g) were obtained from the Primate Facility at Quaid-i-Azam University, Islamabad. The animals were kept under 12 h light/dark cycles at 25 ± 3 °C in conventional steel cages and nourished with regular pellet diet and tap water. The National Institute of animal health guidelines (NIH guidelines) was exactingly followed to conduct the testing efficiently. The ethical board of Quaid-i-Azam University, Islamabad accepted the investigational protocol (Bch\#264). 36 rats were randomly separated into six groups *(n* = 6) and placed in individual steel cages. The study procedure was arranged according to former studies ([@b0300], [@b0155], [@b0280]) with slight adjustments.Group 1: Control group-administered normal saline for 6 weeks (one dose/week, 0.4 ml, i.p.)Group II: Drug control was inoculated with DOX (i.p, 3 mg/kg b.w.) for six weeks (single dose/week, so total dose was18 mg/kg b.w. during 6 weeks).Group III: The plant control group was treated with an oral dose of AHE (400 mg/kg b.w.) daily for 6 weeks.Group IV: DOX + AHE 200 mg/kg; treated with an oral dose of AHE (200 mg/kg b.w) daily for 6 weeks along with DOX inoculation once per week.Group V: DOX + AHE 400 mg/kg; treated with an oral dose of AHE (400 mg/kg b.w) for 6 weeks in conjunction with DOX inoculation once per week.Group VI: DOX + Silymarin; an oral dose of silymarin (400 mg/kg b.w) for 6 weeks in conjunction with DOX inoculation once per week.

The body weights of rats were noted at the beginning and completion of experimentation. 24 h after the last treatment, rats were euthanized by cervical dislocation. Blood was drawn through a direct intra-cardiac puncture and poured in sterile tubes and submitted to centrifugation at 10,000 rpm for 15 min at 4 °C to get the serum. Serum aliquots were placed at −80 °C for further examination. The kidneys were withdrawn and rinsed with ice-cold saline, subsequently, the right kidney was treated with liquid nitrogen and put in storage at −80 °C for biochemical investigations and DNA damage study, while the left kidney was processed in 10% phosphate-buffered formalin for histology.

2.4. Urine analysis {#s0030}
-------------------

Quantity of red blood cells (RBCs), count, white blood cells (WBCs) count, pH, specific gravity, total protein, albumin, urea, creatinine, and creatinine clearance in urine was examined by using standard diagnostic kits (MediScreen Urine Strips, Orgenics, France).

2.5. Biochemical analysis of serum {#s0035}
----------------------------------

Whole protein, albumin, urea, creatinine clearance, and creatinine were examined by standard diagnostic kits (MediScreen kit France). Blood urea nitrogen (BUN), bilirubin, and total protein concentrations were quantified with standard diagnostics kits (AMP Krenngasse 12, 8010 Graz, Australia).

2.6. Biochemical analysis of tissues {#s0040}
------------------------------------

### 2.6.1. Homogenate preparation {#s0045}

Kidney tissue (100 mg) was homogenized in 100 mM KH~2~PO~4~ buffer having 1 mM EDTA, pH 7.4. Then it was centrifuged at 12,000*g* for 30 min (4 °C) to exclude cell debris and the supernatant was stored in aliquots and kept at ~−~20^◦^ C.

### 2.6.2. Assessment of tissue protein {#s0050}

Lowry et al method was used for the assessment of tissue total soluble protein content ([@b0195]).

### 2.6.3. Enzymatic antioxidant measurement {#s0055}

Quantity of CAT and POD was estimated by the procedure of Afsar et al ([@b0025]). The technique of Kakkar *et al*. was employed for the valuation of SOD action ([@b0165]). The amount of quinone reductase in tissues of various experimental groups was calculated as defined previously ([@b0085]). Reduced glutathione quantity was tested as described by Jollow ([@b0160]). The technique of Habig et al. ([@b0135]) was used for the estimation of GST potency. Glutathione reductase activity in tissue samples was examined as cited by Carlberg and Mannervik ([@b0090]). Glutathione peroxidase function was calculated using a previous protocol ([@b0210]). The activity of γ-glutamyl transpeptidase was checked following Orlowski et al scheme ([@b0250]).

### 2.6.4. Assessment of oxidative stress indicators {#s0060}

Iqbal et al. procedure ([@b0145]) were implemented for the calculation of lipid peroxidation. The approximation of hydrogen peroxide range in tissue samples was examined by the scheme described earlier ([@b0255]). For the execution of the nitrite assay, Griess reagent was utilized ([@b0130]).

2.7. DNA damage analysis {#s0065}
------------------------

### 2.7.1. DNA fragmentation test with diphenylamine reaction {#s0070}

DNA fragmentation in renal tissues was analyzed as described previously. 100 mg kidney tissue was homogenized in TTE mixture. 100 µl aliquot (labeled as "B") was centrifuged for 10 min at 200*g* (4 °C). The supernatant was collected and labeled as "S". Then the "S" tubes were centrifuged at 20,000*g* at 4 °C for 10 min to isolate intact chromatin and this was labeled as "T". Afterward, 25% TCA (1.0 ml) was pipetted in all of the labeled tubes and kept overnight at 4 °C. Next, the samples were centrifuged for 10 min at 18,000*g* at 4 °C to recuperate the precipitated DNA. 160 μl of TCA (5%) was added to each tube and heated for 15 min at 90 °C. After that 320 μl of freshly prepared DPA solution was decanted, vortexed, and incubated for 4 hr 37 °C. Optical density was recorded at 600 nm (Smart spec TM Plus, catalog \# 170--2525).

### 2.7.2. Measurement of DNA damage by ladder assay {#s0075}

DNA isolation was carried out by the procedure described previously (Ateşşahín et al.). Renal tissue (100 mg) was rinsed with DNA Buffer before homogenization in 1 ml lysis buffer. Next proteinase K (10 mg/ml, 100 μl) and 10% SDS (240 μl) were poured and agitated slightly and kept overnight in a water bath at 45 °C. Afterward, phenol (0.4 ml) was decanted and agitated for 5--10 min before centrifugation for 5 min (at 3000 rpm, 10 °C). The supernatant was collected and mixed with phenol (1.2 ml) and chloroform/isoamyl alcohol (24:1, 1.2 ml), shake for 5--10 min, and centrifuge at 3000 rpm for 5 min at 10 °C. 25 μl of sodium acetate (pH 5.2, 3 M) and 5 ml ethanol was poured in the supernatant and shake until DNA was precipitated. DNA was splashed with 70% ethanol and then pure DNA was liquefied in TE buffer. The amount of DNA was computed at 260 and 280 nm. 5 μg DNA test sample and 0.5 μg DNA standards were loaded on 1.5% agarose gel. Electrophoresis was executed for 45 min at 100 V batteries (Bio-Rad, electrophoresis apparatus), and DNA was observed below the digital gel doc system (BioRad, Doc XR + System, stain free) and photographed.

2.8. Histopathological examination {#s0080}
----------------------------------

Renal tissues from each group were fixed in a fixative comprising 85 ml absolute alcohol, 5 ml glacial acetic acid, and 10 ml of 40% formaldehyde (10 ml). Tissue samples were mounted in paraffin after dehydration steps to make blocks for microtomy. Tissues were sectioned 4--5 µm with a microtome and stained with Hematoxylin-Eosin (H&E). The slides were examined and photographed under a light microscope (DIALUX 20 EB) at 40X.

3. Results {#s0085}
==========

3.1. Acute toxicity assessment {#s0090}
------------------------------

Ethyl-acetate extract of the *A. hydaspica* exhibited no mortality and toxicity at a maximum concentration of 4000 mg/kg b.w. in acute toxicity experiment after 15 days. Therefore, one-tenth (400 mg/kg b.w) of the highest dose tried in acute toxicity was used for the *in vivo* study of AHE. For dose-dependent response assessment; 200 mg/kg b.w. the dose was also tested in this investigation.

3.2. Effect of AHE against DOX prompted nephrotoxicity {#s0095}
------------------------------------------------------

The protective effect of AHE on DOX-persuaded oxidative stress, biochemical and histopathological alterations in renal tissue were examined by urine analysis, serum analysis, renal tissue antioxidant enzyme status, oxidative stress, and lipid peroxidation. The protective effect exhibited by various treatments was corroborated by analyzing the biochemical and histopathological changes in respective groups.

3.3. Effect on body and kidney weight {#s0100}
-------------------------------------

The influence of AHE co-administration with DOX on the body and renal tissue weight is reported in [Table 1](#t0005){ref-type="table"}. Data showed noteworthy (*p* \< 0.001) reduction in the absolute body weights of DOX inoculated rats in contrast to both control and AHE treatment rats. Co-administration of AHE results in significant weight gain in DOX treated animals, and 400 mg/kg dose seems to be more effective (*p* \< 0.001) in perfecting the weight loss induced by DOX. AHE co-treatment considerably improved renal weight vacillations in contrast to DOX alone administered group.Table 1Effect of DOX and/or AHE treatment on body weight of rats.Treatment (mg/kg)Body weight (g)Kidney weight (g)InitialFinalControl219.0 ± 0.577250.3 ± 0.333^b^2.11 ± 0.03^b\*\*^DOX221.3 ± 0.667226.3 ± 0.661^a^1.88 ± 0.11^a\*\*^AHE alone220.3 ± 0.667248.3 ± 0.671^b^2.10 ± 0.03^b\*\*^DOX + AHE (200)221.7 ± 0.882232.2 ± 0.611^a,b^2.04 ± 0.03DOX + AHE (400)220.3 ± 0.882244.7 ± 0.882^a,b,c^2.1 ± 0.035^b\*\*^DOX + Sily222.0 ± 0.577243.3 ± 0.333^a,b^2.092 ± 0.05^b\*^[^1]

3.4. Renal function markers in urine {#s0105}
------------------------------------

Proper kidney functioning is usually depicted by the composition of urine; therefore urine analysis was performed to notice the variability in kidney function of animals in different treatment groups. The protective efficacy of AHE against DOX provoked alterations in the various urine biomarkers of renal impairment are shown in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}. DOX treatment ensued noteworthy (*p* \< 0.0001) augmentation in urine specific gravity, RBCs and WBCs count, and concentration of urea in the urine while urine PH was dropped significantly (*p* \< 0.0001) in the DOX treated group in comparison to the levels in normal control rats. Co-administration of AHE to DOX treated rats noticeably (*p* \< 0.001) attenuated the above parameters of urine in a dose-dependent manner, thus improving the kidney functions ([Table 2](#t0010){ref-type="table"}).Table 2Physical analysis of urine in various treatment groups.Treatment (mg/kg)pHSpecific gravityRBC/µlWBC/µlUrea (mg/dl)Control7.110 ± 0.050^b^1.042 ± 0.011^b^0.046 ± 0.01^b^15.83 ± 0.291^b^12.77 ± 0.590^b^DOX6.020 ± 0.032^a^1.487 ± 0.019^a^13.35 ± 0.05^a^75.17 ± 0.318^a^41.37 ± 0.876^a^AHE alone7.107 ± 0.029^b^1.041 ± 0.012^b^0.047 ± 0.011^b^15.77 ± 0.233^b^12.57 ± 0.484^b^DOX + AHE (200)6.78 ± 0.103^a\*\*,b,d\*^1.19 ± 0.02^a,b,d^5.930 ± 0.09^a,b,d^40.67 ± 0.278^a,b,d^24.55 ± 0.553^a,b,d^DOX + AHE (400)7.057 ± 0.024^b,c\*^1.06 ± 0.02^b,c\*\*^0.647 ± 0.022^a,b,c^16.07 ± 0.120^b,c^14.43 ± 0.338^b,c^DOX + Sily7.053 ± 0.038^b^1.053 ± 0.020^b^0.618 ± 0.014^a,b^16.17 ± 0.260^b^14.37 ± 0.318^b^[^2]

DOX administration markedly increased the levels of urine creatinine, urinary albumin, and urinary protein while, decreased creatinine clearance capacity as compared to control animals ([Table 3](#t0015){ref-type="table"}). Of the different urinary biomarkers evaluated, an increase in urinary albumin and creatinine revealed high prognostic measure for prediction of advanced DOX-induced nephrotoxicity, defined as primary glomerular damage and secondary tubular injury. Urine albumin and creatinine were more sensitive biomarkers for nephrotoxicity then serum creatinine and serum BUN. AHE co-administration dose-dependently attenuated the DOX-induced toxicity by significantly ameliorating the above parameters compared to animals receiving only DOX. Relatively significant (*p* \< 0.0001) ameliorating effects were recorded with AHE high dose (400 mg/kg b.w) in comparison with low dose group. The levels of creatinine and creatinine clearance restored to that of the control group in the DOX + AHE high dose group, however urinary albumin and protein content were remained significantly (*p* \< 0.05 and *p* \< 0.0001, respectively) high in contrast to control group. DOX + AHE 400 mg/kg b.w. group displayed similar ameliorative effects on urine biomarkers to DOX + silymarin treated group. Oral doses of AHE alone did not induce any difference in urine profile in comparison to control rats.Table 3Effect of Doxorubicin (DOX) and different treatments of AHE on urine creatinine, creatinine clearance, albumin and proteinuria.Treatment (mg/kg)Creatinine (mg/dl)Creatinine clearance (ml/min)Albumin (mg/dl)Urinary Protein (mg/dl)Control0.4033 ± 0.055^b^0.8252 ± 0.064^b\*\*^7.337 ± 0.171^b^23.29 ± 0.761^b^DOX1.387 ± 0.019^a^0.4002 ± 0.043^a\*\*^15.83 ± 0.418^a^54.35 ± 0.805^a^AHE alone0.4007 ± 0.055^b^0.8265 ± 0.065^b\*\*^7.280 ± 0.141^b^23.29 ± 0.025^b^DOX + AHE (200)0.900 ± 0.029^a,b,d^0.5990 ± 0.05511.57 ± 0.348^a,b,d^34.50 ± 0.433^a,b,d\*\*^DOX + AHE (400)0.5077 ± 0.037^b,c^0.7575 ± 0.075^b\*^8.817 ± 0.235^a\*,b,c^27.60 ± 0.432^a,b,c^DOX + Sily0.497 ± 0.035^b^0.7584 ± 0.071^b\*^8.833 ± 0.167^a\*,b^27.17 ± 0.029^a\*\*,b^[^3]

3.5. Effect of AHE on serum kidney function tests {#s0110}
-------------------------------------------------

Like urine profile, serum profile also provides an idea about the kidney function. The level of serum creatinine, urea, uric acid, and BUN was measured to assess DOX-induced nephrotoxicity. DOX treatment significantly (*p* \< 0.0001) decreased serum albumin, protein, and globulin concentration while the quantity of serum urea, uric acid, creatinine, NO, and BUN were considerably (*p* \< 0.0001) elevated in divergence to control group ([Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}). AHE combine treatment perfected the adverse effect of DOX markedly (*p* \< 0.001) by improving the albumin, protein, and globulin and preventing the rise in serum urea, uric acid, creatinine, NO and BUN in a dose-dependent manner. AHE high dose significantly (*p* \< 0.0001) restored the levels of the above-mentioned parameters in comparison to low dose treatment. Administration of silymarin significantly improved the DOX mediated deteriorations in serum biomarkers. Treatment of experimental animals with a high dose of AHE retained the concentration of serum albumin, globulin, creatinine, and uric acid similar to the levels in the control group, while serum protein, BUN, urea and NO content remained significantly different from the control group. AHE alone treatment at 400 mg/kg b.w. showed paralleled response to the control group, depicting the non-lethal influence of plant extract.Table 4Effect of Doxorubicin (DOX) and different treatments of AHE on serum protein, albumin, globulin, BUN, serum nitrite profile.Treatment (mg/kg)Serum proteins (mg/dl)Albumin (mg/dl)Globulin (mg/dl)BUN (mg/dl)Serum nitrite (µM/ml)Control78.06 ± 0.361^b^19.70 ± 0.889^b^58.36 ± 1.246^b^9.167 ± 0.033^b^41.50 ± 0.764^b^DOX37.95 ± 0.396^a^9.367 ± 0.73^a^28.59 ± 1.115^a^23.17 ± 0.561^a^82.37 ± 0.797^a^AHE alone79.06 ± 0.554^b^19.93 ± 0.636^b^59.12 ± 1.078^b^9.133 ± 0.033^b^41.20 ± 0.611^b^DOX + AHE (200)52.19 ± 0.384^a,b,d^15.23 ± 0.176^a\*\*,b^36.95 ± 0.40^a,b,d^17.07 ± 0.23^a,b,d^62.67 ± 0.921^a,b,d^DOX + AHE (400)73.32 ± 0.439^a,b,c^17.78 ± 0.174^b^55.54 ± 0.425^b,c^12.53 ± 0.484^a,b,c^48.13 ± 0.962^a,b,c^DOX + Sily74.62 ± 0.50^a\*\*,b^17.87 ± 0.233^b^56.75 ± 0.333^b^12.37 ± 0.367^a,b^47.23 ± 0.535^a\*\*,b^[^4]Table 5Effect of Doxorubicin (DOX) and different treatments of AHE on serum creatinine, urea and uric acid profile.Treatment (mg/kg)Serum creatinine (mg/dl)Urea (mg/dl)Uric acid (mg/dl)Control0.437 ± 0.032^b^24.03 ± 0.549^b^0.407 ± 0.043^b^DOX2.433 ± 0.089^a^69.33 ± 0.333^a^0.810 ± 0.027^a^AHE alone0.433 ± 0.033^b^23.73 ± 0.857^b^0.403 ± 0.044^b^DOX + AHE (200)1.203 ± 0.009^a,b,d^45.40 ± 0.839^a,b,d^0.707 ± 0.023^a,d\*\*^DOX + AHE (400)0.607 ± 0.018^b,c^30.17 ± 0.441^a,b,c^0.477 ± 0.038^b,c\*\*^DOX + Sily0.593 ± 0.023^b^30.03 ± 0.578^a,b^0.470 ± 0.036^b^[^5]

3.6. Effect of AHE on renal antioxidants {#s0115}
----------------------------------------

[Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"} make evident DOX-induced insufficiency of renal antioxidant enzymes and protective effect of AHE to reduce renal damage with the restoration of renal antioxidant levels. Treatment with DOX-induced a remarkable (*p* \< 0.0001) diminution in renal POD, SOD, CAT, and QR quantity compared to control rats. Simultaneous inoculation of DOX with a high dose of AHE expressively (*p* \< 0.0001) restored renal POD and SOD to the levels statistically similar to control values. However, the level of CAT and QR showed a significant difference to control and DMSO alone treated groups.Table 6Effect of Doxorubicin (DOX) and different treatments of AHE on renal antioxidant enzymes.Treatment (mg/kg)POD (U/min)SOD (U/mg protein)CAT (U/min)QR (nM/min/mg protein)Control10.85 ± 0.150^b^1.752 ± 0.059^b^35.50 ± 0.289^b^93.49 ± 0.526^b^DOX5.570 ± 0.341^a^0.581 ± 0.040^a^18.43 ± 0.251^a^63.55 ± 1.275^a^AHE alone11.30 ± 0.185^b^1.778 ± 0.066^b^35.93 ± 0.479^b^93.84 ± 0.140^b^DOX + AHE (200)8.060 ± 0.017^a,b,d^1.153 ± 0.088^a,b^26.96 ± 0.248^a,b,d^73.32 ± 0.667^a,b,d^DOX + AHE (400)10.07 ± 0.306^b,c^1.647 ± 0.083^b,c\*\*^30.08 ± 0.107^a,b,c^83.22 ± 0.491^a,b,c^DOX + Sily10.02 ± 0.096^b^1.595 ± 0.055^b^30.19 ± 0.335^a,b^83.11 ± 0.537 ^a,b^[^6]Table 7Effect of Doxorubicin (DOX) and different treatments of AHE on renal GSH profile and phase II antioxidants.Treatment (mg/kg)GSH (µM/g tissue)GR (nM/min/mg protein)GST (nM/min/mg protein)γ-GT (nM/min/mg Protein)GPx (nM/min/mg Protein)Control17.41 ± 0.529^b^150.4 ± 0.725^b^139.3 ± 0.355^b^394.4 ± 1.246^b^129.7 ± 1.300^b^DOX9.572 ± 0.323^a^96.22 ± 1.480^a^95.60 ± 0.956^a^107.9 ± 1.156^a^76.85 ± 0.864^a^AHE alone18.38 ± 0.673^b^150.6 ± 0.409^b^139.5 ± 0.442^b^394.8 ± 1.379^b^130.1 ± 1.101^b^DOX + AHE (200)12.90 ± 0.145^a,b,d\*\*^120.2 ± 0.799^a,b,d^110.6 ± 0.298^a,b,d^215.2 ± 0.672^a,b,d^93.00 ± 1.034^a,b,d^DOX + AHE (400)16.63 ± 0.302^b,c\*\*^139.1 ± 1.146^a,b,c^132.5 ± 0.853^a,b,c^362.9 ± 0.610^a,b,c^120.3 ± 1.052^a,b,c^DOX + Sily16.00 ± 0.145^b^138.0 ± 1.201 ^a,b^131.8 ± 1.049 ^a,b^364.5 ± 0.691^a,b^119.6 ± 0.985 ^a,b^[^7]

DOX inoculation caused substantial (*p* \< 0.0001) depletion in renal tissue content of GSH, GR, GST, γ-GT and GPx. The administration of AHE with DOX significantly (*p* \< 0.001) enhanced the level of renal antioxidant enzymes in contrast to only DOX-treated rats, in a dose-dependent manner. Similar levels of GSH, GR, GST, γ-GT, and GPx were recorded in AHE high dose and standard drug silymarin treated groups. Glutathione exhaustion is one of the problems resulting in renal injury, results show that co-administration of AHE at high dose retained level of GSH to normal control values, while the level of activity of GR, GST, γ-GT, and GPx showed a significant difference in contrast to control group. AHE co-treatment with DOX-induced improvement of renal enzymes in a dose-dependent way, indicating that AHE high dose provided better protection as compared to low dose. The high dose of AHE, without DOX treatment, showed no change in renal antioxidant enzymes in comparison to the control group.

3.7. Protective effect of AHE on renal tissue protein and oxidative stress markers {#s0120}
----------------------------------------------------------------------------------

Renal MDA content serves as a marker of renal lipid peroxidation, nitrite/nitrate proportion was taken as an indicator of renal NO concentrations; H~2~O~2~ and NO are important markers of oxidative stress. DOX administration significantly decreased renal tissue protein content and augmented tissue MDA and NO levels in comparison to control. AHE in high dose retrieved the renal protein content, NO, and MDA to the levels statistically insignificant from the control group, while the level of H~2~O~2~ remained significantly different in comparison to control animal tissues. Furthermore, co-administration of AHE high dose showed similar effects to standard drug silymarin by preventing the DOX-induced deterioration. On the other hand, giving AHE in both low and high doses to DOX-inoculated animals improved above said parameters markedly when compared to the DOX alone treated group, but still, the levels were significantly different from control animals. AHE administration alone in high doses showed no substantial influence on renal tissue protein content, H~2~O~2,~ NO, and MDA content in comparison to their levels in the tissue of control animals ([Table 8](#t0040){ref-type="table"}). These results indicated that DOX-induced renal damage involved inconsistency in the ratio of renal tissue oxidant and antioxidant, and AHE showed protection against DOX-induced renal impairments via reversing the altered levels of above-investigated parameters, suggesting a potential role for AHE in DOX-induced nephrotoxicity.Table 8Effect of Doxorubicin (DOX) and different treatments of AHE on renal tissue protein, oxidative stress markers and lipid peroxidation.Treatment (mg/kg)Protein (µg/mg Tissue)H~2~O~2~ (nM/min/mg Tissue)Nitrite (content µM/ml)TBAR (nM/min/mg protein)Control2.530 ± 0.056^b^1.743 ± 0.039^b^47.84 ± 1.156^b^5.026 ± 0.301^b^DOX0.807 ± 0.225 ^a^4.946 ± 0.051^a^85.00 ± 1.055^a^11.92 ± 0.321^a^AHE alone2.470 ± 0.019^b^1.707 ± 0.013^b^45.46 ± 1.302^b^5.007 ± 0.183^b^DOX + AHE (200)1.60 ± 0.043 ^a,b\*\*,d\*^3.381 ± 0.036^a,b,d^66.73 ± 1.620^a,b,d^8.643 ± 0.279^a,b,d^DOX + AHE (400)2.288 ± 0.076^b,c\*\*^2.04 ± 0.047^a\*\*,b,\ c^50.84 ± 1.051^b,c^6.119 ± 0.077^b,c^DOX + Sily2.215 ± 0.039^b^2.109 ± 0.07^a\*\*,c^49.13 ± 1.075^b^6.171 ± 0.191^a\*,b^[^8]

3.8. Molecular analysis of DNA damage {#s0125}
-------------------------------------

### 3.8.1. DNA ladder assay {#s0130}

DNA was isolated from the renal tissues and dissimilar banding conformations were distinguished in [Fig. 1](#f0005){ref-type="fig"}a. The genomic DNA presented a distinct sharp band without dilapidation and tail configuration in the control group. In the case of DOX treated rats, a typical band fragmentation of DNA can be implicit, which was not present for the control group. AHE conducts indicated noticeable restoring of the DNA damage. DNA isolated from the group co-treated with AHE and DOX bared revamped DNA. The group treated with AHE alone did not show any sort of DNA injuries.Fig. 1a**:** Lanes from left (L) low molecular weight marker pattern in a ladder, (1) Control, (2) DOX (3) AHE alone (4) DOX + AHE (200 mg/kg), (5) DOX + AHE (400 mg/kg), (6) DOX + Sily. b: Percent DNA fragmentation in different treatment groups.

### 3.8.2. AHE preclude DOX-prompted % DNA fragmentation {#s0135}

DNA fragmentation (%) exhibited discernible variations in all experimental groups ([Fig. 1](#f0005){ref-type="fig"} b). The AHE treated groups repaired the DOX persuaded DNA damage and reduced the % DNA fragmentation displaying the shielding effects at the genetic level. High dose co-administration of AHE upturned the extent of DNA fragmentation (%) adjacent to the control group.

### 3.8.3. Histopathology of kidney {#s0140}

Light Microscopic sections of renal histology of different treatment groups are shown in [Fig. 2](#f0010){ref-type="fig"}. Histopathological investigation revealed normal morphology of renal glomeruli and cortical tubules in control and AHE alone (400 mg/kg b.w) treated groups. DOX treatment resulted in degenerative changes viz. glomerular atrophy or disappearance; dilated Bowman's capsules and capillaries; and marked disintegration of renal tubules with exfoliated cells, protein casts, and cystic dilatation; blood congestion in the capillary loops; cuboidal or round shape parietal layer of Bowman's membrane; inflammatory cell infiltrations; vocalization in the endothelial cell cytoplasm of proximal tubules and degenerated or lost microvillus. Concomitant administration of AHE with DOX leads to the abrogation of DOX-impelled renal tissue damages in a dose-dependent pattern. DOX + AHE 400 mg/kg b.w. group showed better preserved cellular and tubular structure with the regeneration of renal epithelial cell lining of cortical tubules and reinstatement of regular morphology of renal cortex when compared with DOX alone and AHE 200 mg/kg b.w. groups. The low dose (200 mg/kg b.w.) of AHE however, did not completely reverse morphological alterations observed in DOX alone group and showed moderately degenerated renal tubules, mild atrophy with capsule distortion and tubular dilations of some tubules.Fig. 2Histopathological effect of Doxorubicin and protective effect of AHE in rat kidney (H&E staining, magnification 40X). Group 1: Renal section from control rats showing normal morphology. Group 2: renal sections from DOX-treated rats show degenerative changes, atrophy, capsule distortion, and cellular infiltrations. Group 3: Represents renal section from AHE alone treated rats. Group 4: AHE Low dose treatment showed mild tubular dilations. Group 5: AHE high dose treatment results in significant protection against DOX-induced renal injury. Group 6: Showed a protective effect of Silymarin treatment. AHE-*A. hydaspica* ethyl acetate fraction, DOX- Doxorubicin, GC-Glomerular capsule, BS-Bowman's space, T- Tubules, CI- Cellular infiltrations, ABS-alteration in Bowman's space, TD-Tubule dilation, CD- Capsule distortion, VC-vascular congestions, A- Atrophy.

4. Discussion {#s0145}
=============

The deleterious consequence of DOX-induced nephrotoxicity is mainly governed by selective damaging of proximal tubule cells via mechanisms that continue to be the focus ([@b0125]). Severe renal tubular impairments as a result of chemotherapy lead to acute renal failure ([@b0270]). Inflammation enhances the production of ROS, oxidative stress, apoptosis, and decrease in antioxidant enzymes in the kidney might be the underlying causes of DOX induces renal injury ([@b0010], [@b0095]). Drug-induced amelioration on kidney function and tubular lesions can be easily evaluated by using rat models as their intra‐renal enzyme dissemination is analogous to that in humans ([@b0275]). The current study was proposed to discern the perspective of AHE to prevent the chemotherapeutic drugs induced renal toxicity, which might enhance the antitumor efficacy DOX.

Urine analyses point out the grade of kidney functional capacity and acid-base balance. The elevated level of urine creatinine, urea, protein, and albumin, and decreased creatinine clearance are general indicators of kidney injury impelled by drug treatment([@b0105]). Specifically abnormal proteinuria and hematuria in DOX treated groups indicate nephrotoxicity. Urine specific gravity associated with urine osmolality and provides critical details of hydration status. DOX altered urine specific gravity and PH. Co-treatment with AHE ameliorates DOX-induced alterations in a dose-dependent way.

Inoculation of DOX to rats resulted in lessening in glomerular filtration rate, which is linked with increased serum creatinine, BUN, urea, and uric acid. Current outcomes are in correspondence with earlier outcomes in different studies revealing that boost in the serum levels of renal damage biomarkers concomitant to compromised renal architecture, tubular blockade ([@b0110]). Such functional instabilities in DOX exposed rats point toward the ability of this drugs to prevent protein synthesis in the tubular cells or to recruit lipid peroxidation and grounds free radical formation in renal tissue ([@b0230], [@b0070], [@b0220]). Contrariwise, co-treatment with DOX significantly improved the kidney function biomarkers in serum. Moreover DOX administration decrease kidney tissue protein content and AHE treatments result in significant restoration of kidney tissue protein content.

The decline of SOD, CAT, POD, QR, GPx, γ-GT, GST, and GR activities accompanied by a decrement of GSH content was unveiled after CP and DOX injection, resulting in the reduced ability of the kidney to scavenge toxic H~2~O~2~ and lipid peroxides. These findings were also noticed by other researchers ([@b0110]). In the present investigation, AHE was able to significantly restore the above mentioned antioxidant enzyme activities in kidney tissues. Reno-protective actions of AHE against DOX-induced nephrotoxicity may be due to its unique composition, as AHE fraction of *A. hydaspica* is rich in flavonoids (polyphenolics, tannins, and so forth), and flavonoids have been reported to possess both antioxidant and anti-inflammatory activities via quenching free radicals and impeding lipid peroxidation ([@b0235]). Similarly, green tea intake revealed a marked reduction in the cisplatin-induced oxidative stress via increases in the activities of renal SOD and catalase ([@b0180]). Likewise, Wang and colleagues demonstrated that green tea polyphenols proficiently scavenge ROS production initiated by lead exposure, thus diminished ROS-interceded inflammatory cytokines discharge through ERK/JNK/p38 pathways([@b0305]). Epigallocatechin-3-gallate (EGCG), the main catechin of AHE, is also the chief constituent of green tea extract, is recognized as a dominant antioxidant and ROS scavenger. Numerous studies have shown EGCG has a prospective role in chronic kidney disease models. It is proposed that EGCG modulates cellular and molecular mechanisms via inflammation-allied NF-кB and Nrf2 signaling pathway ([@b0080], [@b0170]). Similarly, Tatlidede and his colleagues demonstrate the protective effect of resveratrol (flavonoid) against DOX prompted cardiotoxicity by lessening oxidative injury ([@b0295]). Among a lot of inducers of oxidative stress, renal MDA and NO were testified to be increased after DOX inoculation. Outcomes of present research also indicate that there was a significant upsurge in MDA, NO, and H~2~O~2~ quantity in the renal tissue of rats that received DOX alone in contrast to the control group. These results were in covenant with preceding studies, which demonstrated an increase in lipid peroxidation and subsidence of antioxidant defense system in the kidney after DOX treatment ([@b0005], [@b0110]). Results reveal that AHE could restore renal injury induced by DOX treatments and confirmed the important role of AHE antioxidant property against drug-induced nephrotoxicity, in particular, via enhancing the antioxidant defense system. Consistently, Abdel Moneim et al. reported that *A. indica* may inhibit lipid peroxidation via quenching free radicals and augmenting intracellular concentration of glutathione owing to the presence of flavonoids ([@b0005]). AHE co-treatment works more efficiently at 400 mg/kg b.w dose compared to 200 mg/kg b.w dose to ameliorate the toxic outcomes of DOX. Induction of nephrotoxicity induced by chemotherapeutic drugs is anticipated to be a quick outcome encompassing reaction proteins in the renal tubules. Hence the nephron-protective mediator must be given at the same time with the chemotherapeutic drug to prevent its side effects. The examination of renal histoarchitecture is necessary to corroborate the biochemical findings of experimental groups. Glomerular capillary tufts size contraction, Bowman's capsule dilation, deterioration, necrosis and detachment of the epithelial cell lining of proximal tubules, flaking of the apical microvilli and accretion of consistent exudates inside the distended tubular lumina of both distal and proximal convoluted tubules were witnessed at the cortico-medullary area in the kidney sections of DOX inoculated rats. Some of the tubules were entirely collapsed and cellular intricacies have vanished. Analogous histopathological findings were demonstrated previously in the kidney of rats treated with altered doses of DOX ([@b0225], [@b0010], [@b0075], [@b0110]). It was assumed that histopathological changes may be linked with the absorption power of renal tubules that initiate functional congestion of nephrons with consequent kidney malfunction ([@b0175]). AHE treatment significantly ameliorates the damaging effects of DOX on kidney morphology. Previous research approves that silymarin possesses excellent renoprotective effect against drug and chemical-induced renal alterations and regarded as a potentially pragmatic candidate in combined chemotherapy regimens by functioning as a potent quencher of radical species in the kidney thus precluding the toxic influences at both the histological and biochemical levels ([@b0285], [@b0060], [@b0240]).

These findings ratified that biochemical and histological variations induced by DOX treatment may be ameliorated by AHE due to the occurrence of active antioxidant polyphenolic metabolites (mainly 7-*O*-galloyl catechin, catechin, and methyl gallate). These compounds might boost cellular antioxidant enzymes, augmented cells GSH amount, and quenched the radical species ([@b0265], [@b0215], [@b0140]). Therefore, AHE might be a significant candidate providing excellent protective effect in combination with chemotherapy due to its antioxidant and radical species quenching potential.

5. Conclusion {#s0150}
=============

By our knowledge, this is the first study indicating the protective effect of *A. hydaspica* on DOX provoked kidney damage in rats. The outcomes revealed the ameliorating potential of AHE against DOX persuaded kidney injury via suppression of DOX mediated oxidative deterioration in renal tubular cells, preservation of kidney function biomarkers, and prevention of DNA damage. Combine administration of AHE at upper tested dose AHE offered added protection against DOX-induced kidney damage. The mechanism of nephroprotective action by AHE fraction could be due to the antioxidant and free radical scavenging activities of its active metabolites*.* The present results suggest that AHE might be a potential therapeutic in preventing DOX nephrotoxic effects. Although AHE showed its protection in our study, it warrants further research for use as therapeutic agents.

Limitations of the study {#s0155}
========================

Further investigations are a prerequisite to endorse the current outcomes using molecular tools and immune-histochemical techniques. There is a necessity for advanced investigations to create an empirical basis for the consumption of *A. hydaspica* as supplementary therapy with DOX, therefore, the details mechanism of *A. hydaspica* effects on anti-inflammatory and anti-apoptotic signaling, the reformative proficiency of the kidneys, and renal cellular transport should be evaluated. Furthermore, due to lack of funding presently we were unable to analyze the details of the mechanism of protection in the xenograft mice model. Therefore, investigating the detailed mechanism of protection and how *A. hydapica* preserve the anticancer potential of DOX in tumor models will be the focus of further investigations.
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[^1]: Data expressed as mean ± SEM (*n* = 6). a: significant difference of final body weight of group Vs. Control group at *p* \< 0.001, b: significant difference of final body weight of group Vs. DOX-treated group at *p* \< 0.001, c: significant difference of final body weight of DOX + AHE (200 mg/kg) treated group Vs. DOX + AHE (400 mg/kg) treated group at *p* \< 0.001.

[^2]: Values expressed as mean ± SEM. a: Significance at *p* \< 0.0001 Vs. control group, b: Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, c: Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d: Significance at *p* \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*\*^: Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin.

[^3]: Values expressed as mean ± SEM. a: Significance at *p* \< 0.0001 Vs. control group, b: Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, c: Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d: Significance at *p* \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*,\ \*\*^: Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin.

[^4]: Values expressed as mean ± SEM. a: Significance at *p* \< 0.0001 Vs. control group, b: Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, c: Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d: Significance at *p* \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*\*^: Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin.

[^5]: Values expressed as mean ± SEM. a: Significance at *p* \< 0.0001 Vs. control group, b: Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, c: Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d: Significance at P \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*,\ \*\*^: Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded etween control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin.

[^6]: Values expressed as mean ± SEM. a: Significance at *p* \< 0.0001 Vs. control group, b: Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, c: Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d: Significance at *p* \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*\*^: Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin.

[^7]: Values expressed as mean ± SEM. a: Significance at *p* \< 0.0001 Vs. control group, b: Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, c: Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d: Significance at *p* \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*\*^: Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin.
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